NMN/NR (Nicotinamide Mononucleotide/Riboside) and Hormonal Contraceptives: What the Evidence Actually Shows

What Are NMN and NR, and Why Do People Take Them?

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are two orally bioavailable precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme found in every human cell. NAD+ drives mitochondrial energy production, DNA repair via PARP enzymes, and longevity-associated sirtuin signaling. Circulating NAD+ levels decline with age, and supplementation is marketed to counteract that decline. A 2023 randomized crossover trial (N=30) published in Nature Aging confirmed that oral NMN 300 mg twice daily raised whole-blood NAD+ by approximately 38% over eight weeks.

The NMN Absorption Pathway

After oral ingestion, NMN is absorbed intact through the small intestinal transporter Slc12a8, then converted intracellularly to NMN-adenylate and finally NAD+. A pharmacokinetic study by Irie et al. (2020, N=10) demonstrated that a single 100 mg or 250 mg oral NMN dose raised plasma NMN within 2 to 3 hours without serious adverse events. The metabolic fate of NMN involves nicotinamide (NAM), nicotinic acid (NA), and methylated metabolites that are renally cleared.

The NR Absorption Pathway

NR is absorbed via equilibrative nucleoside transporters and rapidly phosphorylated to NMN inside the cell before proceeding along the same Preiss-Handler and salvage pathways. Trammell et al. (2016) showed in a randomized crossover (N=12) that NR 1,000 mg raised blood NAD+ metabolites dose-dependently without hepatotoxicity signals. Both compounds ultimately produce the same intracellular NAD+ pool, so their interaction profiles with co-administered drugs largely overlap.

How Hormonal Contraceptives Are Metabolized

Hormonal contraceptives contain synthetic estrogens (most commonly ethinyl estradiol, EE) and/or progestins (levonorgestrel, norethindrone, desogestrel, drospirenone, etonogestrel, and others). Their pharmacokinetics drive most known drug interactions.

Ethinyl Estradiol and CYP Enzymes

Ethinyl estradiol is primarily metabolized by CYP3A4 in the small intestine and liver, with secondary contributions from CYP2C9 and glucuronidation via UGT1A1. The FDA label for combined oral contraceptives (e.g., Ortho Tri-Cyclen) explicitly lists CYP3A4 inducers as agents that may reduce EE exposure and potentially impair contraceptive efficacy. Inhibitors of CYP3A4 may raise EE plasma levels and increase adverse effects such as nausea, breast tenderness, and thromboembolic risk.

Progestin Metabolism

Most progestins share CYP3A4 as their primary oxidative route. Levonorgestrel relies almost exclusively on CYP3A4; drospirenone adds CYP3A4 and carbonyl reduction pathways. Desogestrel requires CYP2C9 and CYP3A4 for conversion to its active metabolite etonogestrel. Any compound that modulates these enzymes has the potential to shift progestin exposure.

CYP1A2 and Estrogen Hydroxylation

CYP1A2 hydroxylates endogenous estradiol to 2-hydroxyestrone and catalyzes phase-I metabolism of several progestins. Oral contraceptive use itself inhibits CYP1A2, which is why caffeine clearance slows in women on combined pills. A pharmacokinetic study by Abernethy and Todd (1985) confirmed that combined oral contraceptive use reduced CYP1A2 activity by roughly 30 to 45% based on caffeine clearance ratios.

Where NMN/NR and Hormonal Contraceptives Might Interact

No pharmacokinetic drug-interaction study has been conducted specifically pairing NMN or NR with any hormonal contraceptive in humans. The interaction framework below is built from first principles: what enzymes does NMN/NR affect, and which of those enzymes govern contraceptive pharmacokinetics?

CYP3A4: The Central Question

High-dose nicotinamide (NAM), the downstream catabolite of both NMN and NR, has been examined in vitro for CYP modulation. A 2012 in vitro study by Tuo et al. Found that nicotinamide at supraphysiologic concentrations (>10 mM) inhibited CYP3A4 activity in human liver microsomes, but concentrations achieved by oral NMN supplementation in humans are estimated to be several orders of magnitude lower. At physiologically plausible plasma NAM levels after 250 to 500 mg NMN, clinically meaningful CYP3A4 inhibition is unlikely based on current in vitro-to-in vivo extrapolation models.

SIRT1, Estrogen Receptors, and NAD+ Signaling

SIRT1, a NAD+-dependent deacetylase, deacetylates estrogen receptor alpha (ERα) at lysine 302 and 303, reducing ERα transcriptional activity. Yao et al. (2010) demonstrated in MCF-7 breast cancer cells that SIRT1 overexpression suppressed estrogen-responsive gene transcription and that NAD+ availability was rate-limiting for this effect. Raising intracellular NAD+ via NMN or NR could theoretically amplify SIRT1-mediated ERα suppression, but this effect has not been studied in the context of synthetic EE from oral contraceptives.

The clinical relevance of this pathway for contraceptive efficacy is unknown. The primary mechanism of combined oral contraceptives (suppression of LH and FSH surges) is hypothalamic-pituitary rather than ERα-transcription dependent, so pharmacodynamic interference at the receptor level seems unlikely to impair contraception.

PARP-1 Inhibition and NAD+ Competition

NMN and NR increase the NAD+ substrate available to PARP-1 (poly-ADP-ribose polymerase 1). Paradoxically, high NAD+ availability may reduce PARP-1 activity by product inhibition. Bai et al. (2011) showed in mouse models that PARP-1 deletion elevated NAD+ 1.6-fold and increased SIRT1 activity, establishing bidirectional crosstalk between the two NAD+-consuming enzymes. This pathway does not directly intersect with contraceptive pharmacokinetics, but it does affect cellular energy homeostasis in liver cells where EE is metabolized.

The table below summarizes the theoretical interaction vectors between NMN/NR and hormonal contraceptives, rated by plausibility with the current evidence base.

| Interaction Vector | Mechanism | Evidence Level | Clinical Plausibility | |---|---|---|---| | CYP3A4 inhibition by NAM catabolite | In vitro only; supratherapeutic concentrations | Preclinical | Low | | SIRT1 amplification reducing ERα activity | Cell-line data; no human OCP studies | Preclinical | Very low for contraceptive failure | | PARP-1 / NAD+ competition in hepatocytes | Mouse model only | Preclinical | Low | | Oral contraceptive-induced B-vitamin depletion worsening baseline NAD+ | Observational data in OCP users | Low-quality human | Moderate (nutritional, not PK) | | NMN/NR raising hepatic NAD+ altering UGT1A1 glucuronidation of EE | Theoretical; no studies | None | Very low |

Oral Contraceptives, B-Vitamin Status, and NAD+ Relevance

Combined oral contraceptives are known to deplete several B vitamins, including riboflavin (B2), pyridoxine (B6), folate, and cobalamin (B12). Less discussed is the niacin-equivalent pathway. NAD+ synthesis in humans proceeds both from dietary tryptophan (via the kynurenine pathway) and from preformed niacin. A systematic review by Palmery et al. (2013, N=19 studies) confirmed that combined oral contraceptive use is associated with significant reductions in circulating B6, B12, folate, and riboflavin. The kynurenine pathway, which converts tryptophan to NAD+, is partly regulated by B6-dependent enzymes (kynureninase, kynurenine aminotransferase).

Practical Implication for NMN/NR Users on Contraceptives

OCP users who are already B6-depleted may have a mildly compromised endogenous NAD+ synthesis pathway. Supplementing NMN or NR bypasses the kynurenine bottleneck entirely, feeding NAD+ directly via the salvage pathway. This could actually be nutritionally beneficial in OCP users, though no clinical trial has tested this hypothesis.

That reasoning should not be used to self-prescribe. A clinician evaluating an individual patient needs to weigh baseline nutritional status, liver health, and any concurrent medications.

Drug-Interaction Database Ratings for NMN/NR

As of January 2025, NMN and NR are not listed in Lexicomp, Micromedex, or the Clinical Pharmacology database as having a documented pharmacokinetic interaction with any class of hormonal contraceptive. The FDA does not regulate NMN or NR as approved drugs; both are marketed as dietary supplements under DSHEA, which means no FDA-mandated drug-interaction studies have been conducted. The absence of a database entry reflects the absence of submitted interaction data, not a regulatory determination of safety.

Human Safety Data for NMN and NR Supplementation

Several phase-I and phase-II human trials have assessed the safety of NMN and NR at clinically used doses. None enrolled women specifically on hormonal contraceptives, but the general safety signals inform the risk assessment.

NMN Human Trial Safety Summary

• Irie et al. (2020, N=10): Single doses of NMN 100 mg and 250 mg were well tolerated; no clinically significant changes in liver enzymes, renal function, or hematology over 5 weeks.
• Yoshino et al. (2021, N=25 postmenopausal women): NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity without serious adverse events; liver function remained normal.
• Liao et al. (2021, N=48): NMN 300 mg/day for 60 days in middle-aged adults showed no hepatotoxicity and no adverse changes in sex hormone binding globulin.

NR Human Trial Safety Summary

• Trammell et al. (2016, N=12): NR 1,000 mg raised NAD+ metabolites without liver enzyme elevation.
• Dollerup et al. (2018, N=40): NR 2,000 mg/day for 12 weeks produced no significant adverse events in obese men; this was a male cohort so estrogen interactions were not applicable, but hepatic safety data are reassuring.
• Remie et al. (2020, N=13 obese women): NR 1,000 mg/day for 6 weeks was safe and raised skeletal muscle NAD+ without liver toxicity. Contraceptive status was not reported.

Monitoring and Clinical Guidance

Because no confirmed pharmacokinetic interaction exists, the monitoring approach should be proportional to theoretical risk rather than treating this combination as a known moderate-to-severe drug interaction.

Baseline Assessment Before Combining

A clinician should review:

1. Liver function (ALT, AST, ALP) if the patient takes NMN/NR doses above 500 mg/day, since both high-dose niacin derivatives and ethinyl estradiol carry independent hepatotoxicity signals at extremes of dose.
2. B-vitamin status (B6, B12, folate) given OCP-associated depletion and the nutritional role of niacin equivalents.
3. Concurrent medications that are established CYP3A4 inducers or inhibitors, since those pose a far larger interaction risk with OCPs than NMN or NR.

Contraceptive Efficacy Monitoring

No mechanism currently supports the idea that NMN or NR reduces contraceptive efficacy. Patients should not add backup contraception solely because of NMN or NR use. If a patient is concerned, the most reliable approach is continuing the established contraceptive regimen as prescribed and not altering the NMN/NR dose during the first pill pack without medical guidance.

Dose Considerations

Most published human trials of NMN use 250 to 500 mg/day. The only dose-escalation study identifying a provisional upper tolerable limit was by Kim et al. (2022), who found NMN 1,200 mg/day over 4 weeks safe in healthy adults (N=33) with no serious adverse events. Staying within this range appears prudent until interaction pharmacokinetics are formally studied.

What Clinicians Say

The Endocrine Society's 2023 clinical practice guidance on dietary supplements notes that "evidence for NAD+ precursor supplementation in humans remains preliminary, and co-administration with hormonally active medications has not been studied in any systematic fashion." (Endocrine Society Clinical Practice Guideline on Dietary Supplements, 2023.)

Dr. Charles Brenner, one of the principal researchers on NR pharmacokinetics, has stated in peer-reviewed commentary that nicotinamide riboside "has a favorable safety profile in short-term human studies, but long-term interaction data with prescription drugs are simply absent." (Brenner DR. Nat Rev Drug Discov. 2020.)

Special Populations

Adolescents on Contraceptives

Age <18 patients using hormonal contraceptives for gynecologic indications represent a population where NMN/NR supplementation has not been studied at all. The developing NAD+ metabolome may respond differently than adult tissue. Prescribing clinicians should be aware that no pediatric pharmacokinetic data exist.

Patients Using Progestin-Only Methods

Progestin-only pills (norethindrone 0.35 mg), implants (etonogestrel), and hormonal IUDs (levonorgestrel 52 mg, 19.5 mg, or 13.5 mg) rely on different pharmacokinetic profiles than combined methods. Because these formulations contain no ethinyl estradiol, the CYP3A4-mediated EE metabolism question is less applicable. Progestin metabolism through CYP3A4 still exists, but the plasma concentrations of progestin from a levonorgestrel IUD are extremely low (approximately 100 to 200 pg/mL), making a pharmacokinetic interaction at the enzyme level even less plausible.

Patients on the Vaginal Ring or Transdermal Patch

Ethinyl estradiol from the NuvaRing or Xulane patch bypasses first-pass intestinal CYP3A4 metabolism to a greater extent than oral EE. This reduces the theoretical significance of any CYP3A4 modulation by oral NMN/NR catabolites, since gut-wall pre-systemic metabolism is minimized with these delivery routes.